You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: antiplatelet drugs reduce pre-eclampsia, preterm birth, and stillbirth or neonatal death

https://doi.org/10.1136/ebm.6.4.107

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) BMJ 322, 329. Duley L, Henderson-Smart D, Knight M, et al.. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review.. Feb 10;. :. –33..
    OpenUrlAbstract/FREE Full Text

    
 
 QUESTION: In pregnant women at risk for pre-eclampsia, how effective are antiplatelet drugs in preventing pre-eclampsia and its complications?

    Data sources

    Studies were identified by searching the Cochrane Pregnancy and Childbirth Group register of trials, the Cochrane Controlled Trials Register, and EMBASE/Excerpta Medica (1994–9) and by handsearching conference abstracts.

    Study selection

    Studies were selected if they were randomised controlled trials comparing antiplatelet drugs with placebo or no antiplatelet drug in women at risk for developing pre-eclampsia. Exclusion criteria were having no clinical data available, inadequate randomisation, <80% follow up of patients, or having participants at very low risk for pre-eclampsia.

    Data extraction

    Data were extracted on study validity (allocation concealment), patient risk for developing pre-eclampsia (high or moderate), length of gestation (< or ≥20 wks), dose of aspirin (≤75 mg or >75 …

    View Full Text

    Footnotes

    • Source of funding: no external funding.

    • For correspondence: Dr L Duley, Resource Centre for Randomised Trials, Institute of Health Sciences, Oxford OX3 7LF, UK. Fax +44 (0)1865 227173.